Potential Future Therapies For Epigenetic Problems

[Guest guest]

I found this abstract while looking for papers for a class. Maybe someday we

will be able to treat epigenetic changes.

http://www.ncbi.nlm.nih.gov/pubmed/21263162

Numerous preclinical and clinical trials, with older as well as some newer

drugs, have demonstrated the targeting of aberrant epigenetic marks to be a

viable means of preventing and treating certain human disorders, including

myelodysplastic and leukemic syndromes and various hemoglobinopathies. These

findings are encouraging, and although the risks associated with such therapy

are largely unknown, precise maps of epigenetic marks are becoming increasingly

available through advancements in sequencing protocols that combine chromatin

immunoprecipitation and gene expression analyses. Indeed, progress in

understanding gene regulation at promoter regions and chromatin organization in

health and disease has been substantial. New insights into the proteins that are

targeted by therapeutic agents that alter epigenetic programs may provide

important inroads into personalized medicine.

[Guest guest]

10 years maybe?

>

> I found this abstract while looking for papers for a class. Maybe someday we

will be able to treat epigenetic changes.

>

> http://www.ncbi.nlm.nih.gov/pubmed/21263162

>

> Numerous preclinical and clinical trials, with older as well as some newer

drugs, have demonstrated the targeting of aberrant epigenetic marks to be a

viable means of preventing and treating certain human disorders, including

myelodysplastic and leukemic syndromes and various hemoglobinopathies. These

findings are encouraging, and although the risks associated with such therapy

are largely unknown, precise maps of epigenetic marks are becoming increasingly

available through advancements in sequencing protocols that combine chromatin

immunoprecipitation and gene expression analyses. Indeed, progress in

understanding gene regulation at promoter regions and chromatin organization in

health and disease has been substantial. New insights into the proteins that are

targeted by therapeutic agents that alter epigenetic programs may provide

important inroads into personalized medicine.

>